Comprehensive Analysis of Prognostic Value and Immune Infiltration of MMP12 in Esophageal Squamous Cell Carcinoma

• Published in: Journal of oncology Vol. 2022; pp. 1 - 11
• Main Authors: Mao, Jing-tao, Lu, Qiang, Jing, Peng-yu, Li, Zi-liang, Yang, Xiao-qi, Zhang, Ji-peng, Li, Zhe
• Format: Journal Article
• Language: English
• Published: Egypt Hindawi 27.02.2022; John Wiley & Sons, Inc
• Subjects: Analysis; B cells; Cancer; Cancer therapies; Esophageal cancer; Extracellular matrix; Genes; Genomes; Medical prognosis; Metastasis; Oncology, Experimental; Prognosis; Squamous cell carcinoma; Tumors; China
• ISSN: 1687-8450; 1687-8450
• DOI: 10.1155/2022/4097428

Esophageal squamous cell carcinoma (ESCC) is a typical neoplastic disease and a frequent cause of death in China. The prognosis of most ESCC patients is still poor. Previous studies demonstrated that MMP12 is involved in tumor metastasis. However, its clinical significance and association with cancer immunity remained largely unclear. In this study, we first analyzed the expressing pattern of MMPs in ESCC from TCGA datasets and found that several MMPs expression was distinctly increased in ESCC. However, only MMP12 expression was associated with five-year survival of ESCC patients. Then, we focused on MMP12 and found its high expression was positively related to advanced clinical stages of ESCC specimens. KEGG assays revealed MMP12 may influence the activity of several tumor-related pathways, such as the Toll-like receptor signaling pathway, TNF signaling pathway, and IL-17 signaling pathway. Then, we sought to determine whether MMP12 expressions were related to immune cell infiltration in ESCC. We observed that increased MMP12 levels were positively associated with the infiltration levels of mast cells activated and macrophages M0. However, eosinophils, B cells naïve, and mast cells resting exhibited an opposite result. Finally, we showed that knockdown of MMP12 suppressed the proliferation of ESCC cells. Overall, our findings proved that high expression of MMP12 may be a novel and valuable prognostic factor in ESCC.